NewAmsterdam Pharma (NAMS) Accounts Payables (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Accounts Payables data on file, last reported at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 32.91% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (up 32.91% YoY), and the FY2025 full-year result was $9.0 million, up 89.08% from the prior year.
• Accounts Payables fell to $8.1 million in Q1 2026, from $9.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $22.7 million in Q2 2023 to a low of $3.6 million in Q3 2025.
• A 5-year average of $9.7 million and a median of $7.6 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 76.77% in 2024 and soared 89.08% in 2025, its largest moves.
• Tracing NAMS's Accounts Payables over 5 years: stood at $18.9 million in 2022, then slipped by 10.35% to $16.9 million in 2023, then slumped by 71.97% to $4.7 million in 2024, then soared by 89.08% to $9.0 million in 2025, then declined by 9.81% to $8.1 million in 2026.
• Business Quant data shows NAMS's Accounts Payables at $8.1 million in Q1 2026, $9.0 million in Q4 2025, and $3.6 million in Q3 2025.